The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Ramipril on Plasma Fibrinolytic Balance in Patients With Acute Anterior Myocardial Infarction
Abstract
Background The long-term administration of ACE inhibitors to selected patients with left ventricular dysfunction appears to reduce the incidence of recurrent myocardial infarction (MI) and unstable angina pectoris. The mechanisms responsible for the reduction in ischemic events are unknown, but likely candidates include effects on the atherosclerotic process, thrombosis, and/or vascular tone. Methods and Results The effects of ACE inhibitor therapy with ramipril on plasma fibrinolytic variables were assessed in 120 subjects participating in the Healing and Early Afterload Reduction Therapy (HEART) study, a double-blind, placebo-controlled trial of acute anterior MI patients who were randomly assigned within 24 hours of the onset of symptoms to receive low-dose ramipril (0.625 mg daily), full-dose ramipril (1.25 mg titrated to 10 mg/d), or placebo for 14 days. Plasma levels of plasminogen activator inhibitor-1 (PAI-1) activity and PAI-1 antigen and tissue plasminogen activator (TPA) antigen were measured before randomization and on day 14. Clinical characteristics of the three study groups were similar, as were the prerandomization plasma levels of PAI-1 antigen, PAI-1 activity, and TPA antigen. Compared with the placebo group, PAI-1 antigen levels were 44% lower ( P =.004) at day 14 in the ramipril-treated patients, and PAI-1 activity levels were 22% lower ( P =.02). In contrast, plasma TPA levels were not significantly different between the placebo-treated and ramipril-treated groups. Conclusions Treatment with ramipril has a significant impact on plasma fibrinolytic variables during the recovery phase after acute MI. The renin-angiotensin system appears to play an important role in the regulation of vascular fibrinolysis, and interruption of this regulatory pathway may contribute to the clinical benefits of ACE inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Self-citationThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cambien, F., Poirier, O., Lecerf, L., Evans, A., Cambou, J.-P., Arveiler, D., Luc, G., Bard, J.-M., Bara, L., Ricard, S., et al. (1992) · Nature · doi:10.1038/359641a0 · Cited by 1,913
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., Faire, U., Dahlén, G., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Hamsten, A., Wiman, B., de Faire, U., & Blombäck, M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512193132501 · Cited by 1,342
Cell-Associated Plasminogen Activation: Regulation and Physiological Functions
Saksela, O., & Rifkin, D. B. (1988) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.04.110188.000521 · Cited by 818
Eriksson, P., Kallin, B., van 't Hooft, F. M., Båvenholm, P., & Hamsten, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.6.1851 · Cited by 739
Alderman, M. H., Madhavan, S., Ooi, W. L., Cohen, H., Sealey, J. E., & Laragh, J. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104183241605 · Cited by 730
MEADE, T. (1993) · The Lancet · doi:10.1016/0140-6736(93)92062-x · Cited by 711
Yusuf, S., Pepine, C. J., Garces, C., Pouleur, H., Rousseau, M., Salem, D., Kostis, J., Benedict, C., Bourassa, M., & Pitt, B. (1992) · The Lancet · doi:10.1016/0140-6736(92)92889-n · Cited by 666
Endogenous tissue-type plasminogen activator and risk of myocardial infarction
Ridker, P. M., Vaughan, D. E., Manson, J., Hennekens, C., & Stampfer, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)90998-v · Cited by 582
Self-citationDawson, S. J., Wiman, B., Hamsten, A., Green, F., Humphries, S., & Henney, A. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82047-6 · Cited by 569
Vaughan, D. E., Lazos, S. A., & Tong, K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117809 · Cited by 530
Self-citationEmerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.
Lonn, E. M., Yusuf, S., Jha, P., Montague, T. J., Teo, K. K., Benedict, C. R., & Pitt, B. (1994) · Circulation · doi:10.1161/01.cir.90.4.2056 · Cited by 503
Ridker, P. M., Gaboury, C. L., Conlin, P. R., Seely, E. W., Williams, G. H., & Vaughan, D. E. (1993) · Circulation · doi:10.1161/01.cir.87.6.1969 · Cited by 400
Self-citationDiurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1).
Angleton, P., Chandler, W. L., & Schmer, G. (1989) · Circulation · doi:10.1161/01.cir.79.1.101 · Cited by 392
Verheijen, J. H., Chang, G. T. G., & Kluft, C. (1984) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1661109 · Cited by 338
[Angiotensin I converting enzyme].
NAKAI, K., Syoh, T., & Hiramori, K. (1995) · PubMed · Cited by 335
Factors Responsible for Impaired Fibrinolysis in Obese Subjects and NIDDM Patients
McGill, J. B., Schneider, D. J., Arfken, C. L., Lucore, C. L., & Sobel, B. E. (1994) · Diabetes · doi:10.2337/diab.43.1.104 · Cited by 310
Prospective study of endogenous tissue plasminogen activator and risk of stroke
Ridker, P. M., Hennekens, C. H., Manson, J. E., Ridker, P. M., Vaughan, D. E., Stampfer, M. J., Vaughan, D. E., Hennekens, C. H., & Stampfer, M. J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90064-7 · Cited by 305
Self-citationKerins, D. M., Hao, Q., & Vaughan, D. E. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118312 · Cited by 304
Self-citationFeener, E. P., Northrup, J. M., Aiello, L. P., & King, G. L. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117786 · Cited by 255
Oikawa, T., Freeman, M., Lo, W., Vaughan, D. E., & Fogo, A. (1997) · Kidney International · doi:10.1038/ki.1997.20 · Cited by 194
Self-citationTissue plasminogen activator release in vivo in response to vasoactive agents
Smith, D., Gilbert, M., & Owen, W. (1985) · Blood · doi:10.1182/blood.v66.4.835.835 · Cited by 179
Ludwig, E., Corneli, P. S., Anderson, J. L., Marshall, H. W., Lalouel, J.-M., & Ward, R. H. (1995) · Circulation · doi:10.1161/01.cir.91.8.2120 · Cited by 173
Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin
Brown, N. J., Nadeau, J., & Vaughan, D. E. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656000 · Cited by 145
Self-citationWright, R. A., Flapan, A. D., Alberti, K. G. M. M., Ludlam, C. A., & Fox, K. A. A. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90543-6 · Cited by 139
Lucore, C. L., & Sobel, B. E. (1988) · Circulation · doi:10.1161/01.cir.77.3.660 · Cited by 136
Diurnal Variation of the Fibrinolytic System
Grimaudo, V., Hauert, J., Bachmahh, F., & Kruithof, E. K. O. (1988) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1647522 · Cited by 134
Almér, L., & Öhlin, H. (1987) · Thrombosis Research · doi:10.1016/0049-3848(87)90147-2 · Cited by 110
Hamdan, A. D., Quist, W. C., Gagne, J. B., & Feener, E. P. (1996) · Circulation · doi:10.1161/01.cir.93.6.1073 · Cited by 92
Ridker, P. M., Vaughan, D. E., Stampfer, M. J., Manson, J. E., Shen, C., Newcomer, L. M., Goldhaber, S. Z., & Hennekens, C. H. (1992) · Circulation · doi:10.1161/01.cir.85.5.1822 · Cited by 77
Self-citationFibrinolytic response during exercise and epinephrine infusion in the same subjects
Chandler, W. L., Veith, R. C., Fellingham, G. W., Levy, W. C., Schwartz, R. S., Cerqueira, M. D., Kahn, S. E., Larson, V., Cain, K. C., Beard, J. C., et al. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90596-f · Cited by 69
Role of the fibrinolytic system in preventing myocardial infarction
Vaughan, D. E., Rouleau, J. L., & Pfeffer, M. A. (1995) · European Heart Journal · doi:10.1093/eurheartj/16.suppl_k.31 · Cited by 34
Self-citationOn the role of bradykinin in secretion from vascular endothelial cells.
EMEIS, J. J., & Tranquille, N. (1992) · PubMed · Cited by 30
Fujii, S., Abendschein, D. R., & Sobel, B. E. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90689-7 · Cited by 28
Cited by
Festa, A., D’Agostino, R., Tracy, R. P., & Haffner, S. M. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1131 · Cited by 1,057
Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction
Packard, R. R. S., & Libby, P. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.097360 · Cited by 925
Cesari, M., Pahor, M., & Incalzi, R. A. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00171.x · Cited by 448
Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events
Ridker, P. M., Brown, N. J., Vaughan, D. E., Harrison, D. G., & Mehta, J. L. (2004) · Circulation · doi:10.1161/01.cir.0000133444.17867.56 · Cited by 422
Self-citationDandona, P., Dhindsa, S., Ghanim, H., & Chaudhuri, A. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002101 · Cited by 386
Metadata
- Authors
- Vaughan, D. E., Rouleau, J.-L., Ridker, P. M., Arnold, J. M. O., Menapace, F. J., & Pfeffer, M. A.
- Venue
- Circulation
- Published
- 1997-07-15
- Volume
- 96
- Issue
- 2
- Pages
- 442-447
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1981594756
- Cited by
- 265
- References
- 36
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.